Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Bagsværd, Denmark, 16 September 2026 – Novo Nordisk today announced that new data from its cardiometabolic pipeline and portfolio will be presented at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2026 in Milan, Italy, from 28 September to 2 October. The data to be presented at EASD will bring new scientific insights shared across obesity, type 2 diabetes, cardiovascular, kidney and liver-related outcomes. Together, the presentations reflect Novo’s continued focus on advancing understanding and treatment of interconnected cardiometabolic diseases to help many more patients.